AstraZeneca, Merck's Lynparza plows ahead in ovarian cancer with $1B-plus approval, phase 3 data

20th December 2018 Uncategorised 0

The year may be winding down, but AstraZeneca and Merck’s Lynparza sure isn’t. It picked up a blockbuster new approval late Wednesday and followed up the act by posting positive phase 3 data Thursday morning.

More: AstraZeneca, Merck's Lynparza plows ahead in ovarian cancer with B-plus approval, phase 3 data
Source: fierce